DNase I levels and disease outcome in JIA patients treated with etanercept

by Damjanov N, Sušić G, Vojinović J, Lazarević D, Bašić J
Published 2011-09-01

Influence of TNFα–308 and T676G TNF-RII polymorphism on response to etanercept and posibility to discontinue tretment

by Nikolic I, Basic J, Lazarevic D, Susic G, Vojinovic J, Damjanov N
Published 2011-09-01

Development and initial validation of a new functional ability tool for juvenile dermatomyositis

by Demirkaya E, Madeo A, Rao AP, Malattia C, Consolaro A, Varnier GC, Lazarevic D, Civino A, Martini A, Ravelli A
Published 2011-09-01

The PRINTO provisional definition of remission in juvenile dermatomyositis

by Kasapcopur O, Ganser G, Ferriani V, Penades I, Dolezalova P, Quartier P, Hofer M, Garay S, Wulffraat N, Pilkington C, Malattia C, Ravelli A, Miettunen P, Pistorio A, Lazarevic D, Melo-Gomes JA, Wierzbowska M, Martini A, Ruperto N
Published 2011-09-01